Trial Profile

A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Retifanlimab (Primary)
Indications Merkel cell carcinoma
Focus Registrational; Therapeutic Use
Acronyms POD1UM-201
Sponsors Incyte Corporation

Most Recent Events

23 Apr 2025 According to an Incyte media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3, 2025, in Chicago.
15 Oct 2024 Status changed from active, no longer recruiting to completed.
09 Sep 2024 This trial has been completed in France, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com